Endometriosis
Conditions
Interventions
Once-daily oral administration of SR-16234 for 12 weeks
Sponsors
Tottori University Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Patient wiht menstrual cycle 2) Patient with diagnosis of chocolate cyst of the ovary by echography or MRI 3) Patient with pelvic pain associated with endometriosis
Exclusion criteria
Exclusion criteria: 1) Patient with estrogen-dependent cancer or cervical cancer 2) Patient with diagnosis of fibroid (longest diameter > 3 cm) 3) Patient with non-diagnosis of abnormal genital bleeding 4) Patinet with medical history of osteoporosis, bone loss or other metabolic disease 5) Treatment with luteal hormone or follicular hormone-based hormone agents, low dose pill, middle dose pill, GnRH agonist, testosterone derivative, follicular hormone antagonist, or aromatase inhibitor within 2 months of initiation of administration 6) Treatment with transvaginal alcohol fixative, surgical therapy by laparotomy or laparoscope within 3 months of initiation of administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pelvic pain | — |
Secondary
| Measure | Time frame |
|---|---|
| Algomenorrhea, objective, adverse experience | — |
Countries
Japan
Contacts
Public ContactFuminori Taniguchi
Tottori University Hospital Devision of reproductive-perinatal and gynecologic oncology
Outcome results
None listed